Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Go back to Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 22.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.60 | 52 Week High | $42.49 | |||
| Open | $22.60 | 52 Week Low | $16.64 | |||
| Day High | $22.60 | P/E | N/A | |||
| Day Low | $22.60 | EPS | $-0.42 | |||
| Volume | 137 | |||||
